Hypogonadism Treatment Market Size, Share, and COVID-19 Impact Analysis By Therapy (Testosterone Replacement Therapy, Estrogen Therapy, and Progesterone Therapy), By Route of Administration (Oral, Parenteral, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Regional Forecast, 2024-2032

Hypogonadism occurs due to less or no production of hormones by the body's sex glands (gonads/ ovaries). Hypogonadism is caused by various factors, including genetic, menopausal, autoimmune, and viral diseases. It may also develop after cancer treatments such as radiation and chemotherapy. This condition is most common in aging males and females. According to an article published by the National Institutes of Health (NIH) in 2022, hypogonadism affects approximately 40.0% of men over 45 years of age, and 50.0% of men above 80 years. Hypogonadism treatment mainly involves hormone replacement therapies that help to restore fertility in men and women.

The rising prevalence of hypogonadism is increasing the adoption of hormonal therapies. Such substantial product demand is boosting market growth. Also, growing research and strategic activities to introduce advanced hypogonadism products are expected to create substantial opportunities in the market.  

However, hormone therapies for hypogonadism are associated with huge costs depending on factors including the type of medication, dosage, mode of administration, and insurance. The high cost of such therapies limits the market expansion.

Impact of COVID-19 on the Hypogonadism Treatment Market

The global hypogonadism treatment market had a negative impact due to the COVID-19 pandemic. The restrictions enacted due to the COVID-19 pandemic declined the number of patient visits for hypogonadism across the globe. However, many patients opted for telemedicine during the pandemic. For instance, according to an article published by Science Direct in 2021, compared to the office visits in April 2019, male sexual medicine visits in April 2020 peaked because of telemedicine use.

Furthermore, the COVID-19 pandemic disrupted the supply chain of the companies and the cancellation of various product launches. It also resulted in a delay of clinical trial programs of the major key player in the market. However, the market returned to the pre-pandemic growth rate and is expected to attain substantial growth during the forecast period.

Key Insights

• Prevalence of Hypogonadism Treatment, By Key Countries, 2022.


• Key Industry Developments – Mergers, Acquisitions, and Partnerships.


• New Product Launches, By Key Players.


• Overview: Alternative Therapies for the Treatment of Hypogonadism.


• Impact of COVID-19 on the Hypogonadism Treatment Market.

Analysis by Treatment Type:

Based on the treatment type, the global hypogonadism treatment market is segmented into testosterone replacement therapy, estrogen therapy, and progesterone therapy. Testosterone replacement therapy is expected to hold the dominant share of the market. The rising prevalence of hypogonadism among males and significant strategic initiatives by major key players contribute to the market’s growth. In July 2022, Grünenthal signed an agreement to acquire Bayer AG’s product Nebido for up to € 500 million (USD 595.2 million). The product Nebido is one the leading brands in treating male hypogonadism. Such factors positively drive market growth.

Regional Analysis:

Among the regions, North America gained the topmost position in the share and size of the global market. ­­The dominance of North America is attributed to significant product approvals from regulatory bodies and suitable reimbursement facilities. In August 2022, The U.S. Food and Drug Administration (FDA) approved Kyzatrex (testosterone undecanoate) for testosterone replacement therapy in adult males. Also, the increasing prevalence of hypogonadism and vital research initiatives propel regional growth.

Key Players Covered

The report will include the profiles of key players such as Abbott, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Endo International plc, Ferring B.V., Gedeon Richter, Pfizer Inc. and others.

Segmentation

Key Industry Developments

• February 2023: Gedeon Richter Plc. signed a licence agreement with Mithra Pharmaceuticals for the commercialisation of Donesta. The product Donesta is a next-generation orally-administrated estetrol (E4)-based hormone therapy candidate used for a potential long-term solution to treat the different symptoms of menopause.


• October 2022: Clarus Therapeutics Holdings, Inc. completed an auction for the sale of JATENZO and the selection of Tolmar, Inc. as the successful bidder.


• June 2022: Clarus Therapeutics Holdings, Inc presented new data at JATENZO (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s annual meeting.